ELVN · Enliven Therapeutics, Inc.

內部人交易（Form 4）· Insider trading · 2026-07-01 – 2026-10-22

Enliven Therapeutics, Inc.（ELVN）內部人交易：2026-07-01 至 2026-10-22，內部人公開市場買入 —、賣出 $12.9M；高管董事有效買入 —、有效賣出 —。最近申報 2026-10-21。

買入 Bought—

賣出 Sold$12.9M

有效買入 Effective bought—

有效賣出 Effective sold—

最近申報 Recent filings

交易日	內部人	類型	股數	價格	金額
2026-10-19	Collins Helen Louise CHIEF MEDICAL OFFICER	賣出 Sell	5,000	$38.47	$192K	SEC
2026-10-19	Hohl Benjamin CHIEF FINANCIAL OFFICER	賣出 Sell	6,018	$38.48	$232K	SEC
2026-10-01	Garland J. Scott Director	賣出 Sell	13,000	$46.67	$607K	SEC
2026-09-17	Collins Helen Louise CHIEF MEDICAL OFFICER	賣出 Sell	5,000	$50.35	$252K	SEC
2026-09-17	Hohl Benjamin CHIEF FINANCIAL OFFICER	賣出 Sell	6,018	$50.35	$303K	SEC
2026-08-17	Collins Helen Louise CHIEF MEDICAL OFFICER	賣出 Sell	5,000	$58.59	$293K	SEC
2026-08-17	Hohl Benjamin CHIEF FINANCIAL OFFICER	賣出 Sell	6,018	$58.58	$353K	SEC
2026-08-04	Derynck Mika K Director	賣出 Sell	158,795	$60.21	$9.6M	SEC
2026-07-17	Collins Helen Louise CHIEF MEDICAL OFFICER	賣出 Sell	5,000	$52.67	$263K	SEC
2026-07-17	Hohl Benjamin CHIEF FINANCIAL OFFICER	賣出 Sell	6,018	$52.64	$317K	SEC
2026-07-06	Kunkel Lori Anne Director	賣出 Sell	10,000	$50.49	$505K	SEC

「有效」= 高管或董事的公開市場主動買賣，排除 10b5-1 計劃、行權賣出、繳稅賣出、IPO/認購等。

預計出售日	申報人	股數	約金額
2026-10-19	Collins Helen Louise Director	15,000	$560K	10b5-1
2026-10-01	Garland J. Scott Director	13,000	$607K
2026-09-17	Hohl Benjamin Officer	12,036	$591K	10b5-1
2026-09-04	Heyman Richard A. resigned from BOD	38,000	$2.3M
2026-08-04	Derynck Mika K Director	158,795	$9.2M	10b5-1
2026-07-17	Collins Helen Louise Officer	15,000	$763K	10b5-1

Collins Helen Louise、Hohl Benjamin、Garland J. Scott、Derynck Mika K、Kunkel Lori Anne